

Date: 10th February 2026

To, Manager,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 533315

Dear Sir/Madam,

Sub: Investor Presentation for the quarter and nine months ended December 31, 2025

With reference to the subject, please find enclosed the Investor Presentation for the quarter and nine months ended December 31, 2025.

Kindly take the above information on record.

Thanking You,

**For Innovassynth Technologies (India) Limited
(Formerly known as Innovassynth Investments Limited)**

**Sameer Pakhali
Company Secretary & Compliance Officer
ACS 55746**

**Innovassynth Technologies (India) Limited
(Formerly, Innovassynth Investments Limited)**

Registered office:

Old Mumbai-Pune Road,
Khopoli – 410 203, India.
Phone: +91-2192-260100
Email: itil@innovassynth.com
CIN: L67120MH2008PLC178923

Corporate Office:

TCG International Biotech Park,
2nd Floor, Genesis Square,
Hinjewadi Phase – II,
Pune – 411 057, India.
Phone: +91-20-61921000



INNOVASSYNTH

Investor Presentation Q3FY26

10-February-2026

**Chemistry of
possibilities**



Disclaimer

This presentation has been prepared by Innovassynth Technologies India Limited (formerly known as Innovassynth Investments Limited).

The presentation aims to cover key financial and business highlights. The words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “will,” “may,” “should” and similar expressions identify forward-looking statements. Forward-looking statements are inherently subject to a variety of risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected. These include, without limitation, risks relating to the execution of strategic initiatives, global supply chain, technological developments, exposure to market volatility, geopolitical developments and other associated risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

This presentation does not aim to offer, and should not be viewed as providing, a complete or comprehensive assessment of the Company’s business, financial performance, operating results, market position, or prospects. Further, this presentation is not an offer, solicitation, or invitation to buy or subscribe for any securities of the Company, nor should it be relied upon for any contractual or investment decision.



Business Model

Innovassynth has 3 business units



Life Sciences & Nucleosides



Specialty Chemicals



Contract Research
Development and
Manufacturing

Exports Led Business : ~90% of revenue from global geographies with key focus on US & EU.

Our Life Sciences & Specialty Chemicals segments focus on developing niche products for customers, resulting in higher profit margins

State of the art manufacturing facility



Integrated Manufacturing Facility
at Khopoli, near Mumbai, India



9 multipurpose manufacturing plants built to handle a wide range
of chemical processes and production scales

CRDMO - Our comprehensive CRDMO services, from concept to commercialization

- Custom Research
- Contract Manufacturing
- Full Time Equivalent/Fee for Service
- Scale up to Commercial Products
- 50+ highly qualified scientists specializing in specialty intermediates, bulk chemicals for various applications
- Custom development and manufacturing as per customer requirements



Innovassynth: At a Glance

Infrastructure



60+
Acres of world class infrastructure including mfg. plant in Khopoli, near Mumbai area

People



300+
Total strength

Service Capability



Custom Research, Development & Manufacturing (CRDMO), HQ and R&D in Pune, India

Quality Standards



ISO 27001:2022,
ISO 14001:2015,
ISO 45001:2018,
ISO 9001:2015

Manufacturing Capability



9
Production plants in a single manufacturing complex

R&D Capability



50+
Scientists including 10+ PhDs, 100+ technical staff



Ecovadis Gold Rating
for the second consecutive year



SBTi being initiated in 2026

Global Customer Base




100+
Customers across specialty chemicals and life sciences-nucleosides



Financial Highlights

	Revenue	EBIDTA	PAT
Q3 FY26	INR 22 Cr YTD INR 52 Cr	INR (4.5) Cr YTD INR (31) Cr	INR (7.5) Cr YTD INR (40.6) Cr

- Company has a pipeline of products at various stages of commercialization. This augurs well for the long-term business prospects
- For all regular products we work on backward integration and process improvements to enhance yields and strengthen competitiveness in the international markets
- As the Company operates in a B2B environment, orders for a particular quarter may shift to subsequent quarters. Accordingly, full-year financial statements provide a more accurate view of operational results
- The company's revenue is primarily export-driven, with the majority of business coming from USA and Europe. Domestic and other markets contribute minimally.





Order Book Position

Company has a strong order book and has recently secured several promising new orders from U.S.-based Companies

Life Sciences	Specialty Chemicals	CRDMO	TOTAL
INR 65 Cr	INR 8 Cr	INR 73 Cr	INR ~146 Cr



Consolidated Profit and Loss Statement

Particulars	Quarter Ended			Year Ended
	31-Dec-2025	30-Sep-2025	31-Dec-2024	31-Mar-2025
Revenue from operations	2,197	1,728	4,991	9,831
Other Income	11	30	120	178
Total Income	2,208	1,758	5,111	10,009
Material Cost	354	739	1,649	3,583
Employee Benefits Expenses	921	845	875	1,469
Other Expenses	1,330	1,253	1,326	2,620
Total Expenses	2,604	2,838	3,850	7,671
Finance Cost	189	176	179	353
Depreciation and amortisation expense	197	199	195	388
Profit/(loss) before exceptional items and tax	(783)	(1,454)	887	1,596
Exceptional items	50	21	4	33
Profit/(loss) before tax	(833)	(1,476)	883	1,563
Tax expenses/(credit)	(53)	(48)	(36)	(452)
Profit/(loss) for the period	(780)	(1,428)	919	2,015
Other comprehensive income/(loss)	15	-	(21)	(10)
Total comprehensive Income/ (Expense) for period	(764)	(1,428)	899	2,005

Amount in
INR Lakhs

Previous year audited figures cover only the post-merger period (Oct 2024 – Mar 2025). Pre-merger losses (Apr–Sep 2024 to the tune of Rs 33.74 crores are excluded, so current period comparisons should be viewed in this context.

INN  VASSYNTH

Thank You

